Press Release

POZEN Forms an Irish Subsidiary and Enters into an Intangible Property Transfer Arrangement

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 2, 2015--
POZEN Inc. (NASDAQ: POZN),a pharmaceutical company
committed to developing medicine that transforms lives, today announced
that it has formed POZEN Limited, a wholly owned Irish subsidiary and
has entered in an Intangible Property Transfer Arrangement between POZEN
Inc. and POZEN Limited.

The company has been evaluating its strategic options since recovering
the U.S. commercial rights on YOSPRALA in November 2014 and recently
announced hiring Adrian Adams as Chief Executive Officer and Andrew
Koven as President and Chief Business Officer to lead the strategic
effort. In anticipation of the approval and commercialization of
YOSPRALA, the potential for significant global business and commercial
activities and the expected financial benefits arising therefrom, the
company is developing a plan to expand its geographic footprint and
increase its foreign presence, including potential international sales,
manufacturing and product development.

“We are planning to build a specialty pharmaceutical business at POZEN,
by maximizing the value of YOSPRALA as a core asset upon its approval
and by strategically growing the business through product and corporate
development activities aimed to position POZEN for its next stage of
growth,” said Adrian Adams, Chief Executive Officer of POZEN Inc. “Our
initial therapeutic focus will be in the cardiovascular space with a
consideration for other product opportunities to broaden our overall
portfolio and increase POZEN’s geographic footprint.”

About POZEN

POZEN Inc. is a small pharmaceutical company that specializes in
developing novel therapeutics for unmet medical needs and licensing
those products to other pharmaceutical companies for commercialization.
By utilizing a unique in-source model and focusing on integrated
therapies, POZEN has successfully developed and obtained FDA approval of
two self-invented products. Funded by these milestones/royalty streams,
POZEN has created a portfolio of cost-effective, evidence-based
integrated aspirin therapies designed to enable the full power of
aspirin by reducing its GI damage.

The Company's common stock is traded under the symbol “POZN” on The
NASDAQ Global Market. For more detailed company information, including
copies of this and other press releases, please visit www.pozen.com.

About YOSPRALA

POZEN has created a portfolio of investigational integrated aspirin
therapies - the PA product platform. The products in the PA portfolio
are being developed with the goal of significantly reducing GI ulcers
and other GI complications compared to taking enteric-coated or plain
aspirin alone.

The first candidates are YOSPRALA 81/40, containing 81 mg of aspirin,
and YOSPRALA 325/40, containing 325 mg of aspirin. Both products are a
coordinated-delivery tablet combining immediate-release omeprazole (40
mg), a proton pump inhibitor, layered around a pH-sensitive coating of
an aspirin core. This novel, patented product is intended for oral
administration once a day and an indication is being sought for use for
the secondary prevention of cardiovascular disease in patients at risk
for aspirin-induced gastric ulcers.

Forward-Looking Statements

Statements included in this press release that are not historical in
nature are “forward-looking statements” within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act of
1995. You should be aware that our actual results, our ability to return
value to our stockholders, including any cash distributions, and our
future prospects could differ materially from those contained in the
forward-looking statements, which are based on current market data and
research (including third party and POZEN sponsored market studies and
reports), management’s current expectations and are subject to a number
of risks and uncertainties, including, but not limited to, our inability
to further license our YOSPRALA product candidates on terms and timing
acceptable to us, our inability to build, acquire or contract with a
sales force of sufficient scale for the commercialization of Yosprala in
a timely and cost-effective manner, our failure to successfully
commercialize our product candidates; costs and delays in the
development and/or FDA approval of our product candidates, including as
a result of the need to conduct additional studies or due to issues with
third-party manufacturers, or the failure to obtain such approval of our
product candidates for all expected indications, including as a result
of changes in regulatory standards or the regulatory environment during
the development period of any of our product candidates; uncertainties
in clinical trial results or the timing of such trials, resulting in,
among other things, an extension in the period over which we recognize
deferred revenue or our failure to achieve milestones that would have
provided us with revenue; our inability to maintain or enter into, and
the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products,
including our dependence on AstraZeneca and Horizon for the sales and
marketing of VIMOVO®, our dependence on Patheon
for the manufacture of YOSPRALA 81/40 and YOSPRALA 325/40; competitive
factors; our inability to protect our patents or proprietary rights and
obtain necessary rights to third party patents and intellectual property
to operate our business; our inability to operate our business without
infringing the patents and proprietary rights of others; general
economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events, including those discussed herein and in
our Annual Report on Form 10-Q for the period ended March 31, 2015. We
do not intend to update any of these factors or to publicly announce the
results of any revisions to these forward-looking statements.